Effects of ultrafine particles on the allergic inflammation in the lung of asthmatics: results of a double-blinded randomized cross-over clinical pilot study

Part Fibre Toxicol. 2014 Sep 10:11:39. doi: 10.1186/s12989-014-0039-3.

Abstract

Background: Epidemiological and experimental studies suggest that exposure to ultrafine particles (UFP) might aggravate the allergic inflammation of the lung in asthmatics.

Methods: We exposed 12 allergic asthmatics in two subgroups in a double-blinded randomized cross-over design, first to freshly generated ultrafine carbon particles (64 μg/m³; 6.1 ± 0.4 × 10⁵ particles/cm³ for 2 h) and then to filtered air or vice versa with a 28-day recovery period in-between. Eighteen hours after each exposure, grass pollen was instilled into a lung lobe via bronchoscopy. Another 24 hours later, inflammatory cells were collected by means of bronchoalveolar lavage (BAL). (

Trial registration: NCT00527462) RESULTS: For the entire study group, inhalation of UFP by itself had no significant effect on the allergen induced inflammatory response measured with total cell count as compared to exposure with filtered air (p = 0.188). However, the subgroup of subjects, which inhaled UFP during the first exposure, exhibited a significant increase in total BAL cells (p = 0.021), eosinophils (p = 0.031) and monocytes (p = 0.013) after filtered air exposure and subsequent allergen challenge 28 days later. Additionally, the potential of BAL cells to generate oxidant radicals was significantly elevated at that time point. The subgroup that was exposed first to filtered air and 28 days later to UFP did not reveal differences between sessions.

Conclusions: Our data demonstrate that pre-allergen exposure to UFP had no acute effect on the allergic inflammation. However, the subgroup analysis lead to the speculation that inhaled UFP particles might have a long-term effect on the inflammatory course in asthmatic patients. This should be reconfirmed in further studies with an appropriate study design and sufficient number of subjects.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Air Pollutants / chemistry
  • Air Pollutants / toxicity*
  • Asthma / complications*
  • Asthma / physiopathology
  • Bronchial Provocation Tests
  • Carbon / administration & dosage
  • Carbon / chemistry
  • Carbon / toxicity
  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Humans
  • Inhalation Exposure / adverse effects*
  • Lung / drug effects*
  • Lung / immunology
  • Lung / physiopathology
  • Male
  • Middle Aged
  • Particle Size
  • Particulate Matter / administration & dosage
  • Particulate Matter / chemistry
  • Particulate Matter / toxicity*
  • Pilot Projects
  • Pneumonia / chemically induced*
  • Pneumonia / complications
  • Pneumonia / immunology
  • Pneumonia / physiopathology
  • Respiratory Hypersensitivity / complications
  • Respiratory Hypersensitivity / etiology*
  • Respiratory Hypersensitivity / immunology
  • Respiratory Hypersensitivity / physiopathology
  • Respiratory Mucosa / drug effects
  • Respiratory Mucosa / immunology
  • Respiratory Mucosa / physiopathology
  • Severity of Illness Index

Substances

  • Air Pollutants
  • Particulate Matter
  • Carbon

Associated data

  • ClinicalTrials.gov/NCT00527462